Tobira crushed after NASH drug flunks a PhIIb, but slice of data drives PhIII plans
Tobira Therapeutics’ $TBRA lead drug cenicriviroc flunked a Phase IIb study for NASH, but the South San Francisco-based biotech says it got enough positive data on a secondary endpoint to warrant a move into a pivotal Phase III program,.
Tobira’s shares were crushed by the news, plunging 64% in premarket trading.
The primary endpoint in the study, which registered 289 patients, was a drop in a score for disease activity in NASH, a fatty liver ailment that has been growing at an epidemic pace around the world. On that point, the drug flopped. It also failed a secondary endpoint for complete resolution of steatohepatitis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.